Sign in
Not yet recruitingPhase 4

Amara-Tropfen drops compared with placebo for irritable bowel syndrome

Tests Amara-Tropfen against placebo for discomfort in adults with irritable bowel syndrome.

Key facts

Who runs it
Weleda AG
Where
Germany8 sites in 1 countryChoose a country to see its sites
Registry title
Amara-Tropfen vs. placebo for irritable bowel syndrome (IBS)
Status
Not yet recruiting
Phase
Phase 4
People taking part
106 people, planned
Started
1 Sept 2026
Expected to end
30 Jun 2027
Type of study
Interventional
Record updated
1 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with irritable bowel syndrome (IBS) who have marked bowel discomfort. It compares Amara-Tropfen (Amara drops) with a placebo (dummy drops).

Age
18 to 75 years
Sex
All sexes can join.
Disease stage
IBS by the German IBS guideline (2021): bowel complaints for longer than 3 months, or coming back, that affect quality of life. Average discomfort of at least 40 mm on a 100 mm scale over 7 days. IBS-SSS score of 175 or more. BMI of 40 or less.
Earlier treatment
No drug with the ingredients of Amara-Tropfen now or in the 28 days before baseline. No change in IBS drugs or doses, or in other relevant treatment, in the last 28 days.
Biomarker or test result
Under 50 years: a normal colonoscopy (bowel camera test) in the last 5 years, or a stool calprotectin under 100 mg/kg in the last 8 weeks. 50 years or older: a normal colonoscopy in the last 5 years is required.

Main reasons for not taking part

  • Pregnancy or breastfeeding
  • Diabetes type I or type II, cancer in the past 5 years, or serious kidney, liver or lung disease
  • Major belly surgery in the last 5 years
  • Strong anxiety or depression (HADS score 14 or more), or severe diarrhoea or constipation
  • Allergy to chicory (Cichorium), other Asteraceae plants or the drops' ingredients

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Patients (all genders/sexes) ≥ 18 to ≤ 75 years at inclusion
  • Patients with diagnostic criteria of Irritable Bowel Syndrome (German IBS guideline, 2021) and - for patients younger than 50 years at screening a normal colonoscopy not older than 5 years or stool Calprotectin value of <100 mg/kg not older than 8 weeks at screening - for patients with an age of 50 years or older at screening a normal colonoscopy not older than 5 years is mandatory. Definition according to German guideline: The disease of irritable bowel syndrome (RDS; Irritable Bowel Syndrome/IBS) is present if all 3 points (a-c) are fulfilled. a. There are chronic, i.e. lasting longer than 3 months or recurrent complaints (e.g. abdominal pain, flatulence), which the patient and doctor relate to the bowel and are usually accompanied by changes in bowel movements. b. the complaints should justify the patient seeking help and/or worrying about them and be severe enough to have a relevant impact on quality of life. c. the prerequisite is that there are no changes characteristic of other clinical pictures that are probably responsible for these symptoms
  • Mean discomfort intensity of ≥ 40 mm on a Visual Analogue Scale (VAS) (out of 100 mm) over 7 days – assessed before baseline (visit 2)
  • Irritable Bowel Syndrome Severity Scoring System (IBS-SSS) ≥ 175 at inclusion and baseline
  • Body mass index (BMI) ≤ 40 at inclusion
  • Patients willing and able to follow the trial assessments and trial procedure for the entire trial duration
  • Female patients of childbearing potential using highly efficient contraceptive methods from screening throughout the study until visit 5
  • Signed informed consent prior to any trial related procedure

Who cannot take part

  • Administration of any drug containing active ingredients of Amara-Tropfen (currently or within 28 days prior to baseline (visit 2))
  • Concurrent participation in another clinical study or administration of an IMP in another clinical trial within 3 months prior to screening visit or within five half-lives, whichever is longer
  • Administration of not permitted therapy (for details see sections “prior and concomitant therapy”)
  • Change in relevant medical treatment during the last 28 days prior to baseline (visit 2) (e.g., proton pump inhibitor, antidepressants) or planned for the duration of the study
  • Change of any drug or dose for IBS during the last 28 days prior to baseline (visit 2)
  • Clinically relevant psychiatric comorbidity (Hospital Anxiety and Depression Scale [HADS] score ≥14 each
  • Known hypersensitivity against / intolerability to Cichorium, other Asteraceae or constituents of the IMP
  • Any condition that interferes with the participation in the clinical study at the discretion of the investigator (e.g. known drug, alcohol abuse, presence of severe diarrhea defined as watery or loose stool more than three times daily or severe constipation defined as hard stool less than three times a week)
  • Participants, who are inmates of psychiatric wards, prison or state institutions
  • History of major abdominal surgery (appendectomy, hysterectomy, cholecystectomy, hernia repair are not exclusion criteria) within the last 5 years
  • Known active severe infection diseases
  • Known diabetes mellitus type I and/or type II
  • Known existing relevant somatic condition (e.g. severe impaired renal function, severe liver disease, severe pulmonary disease, severe long/post COVID)
  • History of or known existing malignancy during the past 5 years before screening visit except for history of basal cell carcinoma and melanoma in situ
  • Positive urine pregnancy test (applicable for female participants of childbearing potential) or lactation
  • Patients who are staff of the study sites, staff of the CRO or the sponsor company or a member of the trial team

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

1. To investigate the efficacy of verum compared to placebo in patients with IBS in terms of the change in intensity of discomfort using the weekly mean of a VAS after randomization until the end of the treatment period compared to baseline (=7 days prior to randomization).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
A prospective, exploratory, parallel-group, low-intervention, phase IV, randomized, double-blind, placebo-controlled, multi-center, national, 2-arm trial to investigate efficacy and safety of Amara-Tropfen (Amara drops) in patients with irritable bowel syndrome (IBS)
Plain-language title
Amara-Tropfen drops compared with placebo for irritable bowel syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
1 October 2026